Empire Building: Jardiance To Take ‘Special Place’ In Heart Failure

Boehringer And Lilly 'Urgently' Submitting EMPEROR-Preserved Data

Sep 02 2021

• By Kevin Grogan

Listen to this article

Boehringer Ingelheim’s cardiometabolism head Mohamed Eid considers the impact of EMPEROR-Preserved study on the heart failure treatment landscape and looks ahead at potential new conquests in kidney disease for its SGLT2 inhibitor.

Boehringer Ingelheim headquarters in Ingelheim, Germany — Jardiance turning into a megablockbuster for Boehringer Ingelheim • Source: Archive (dieth+schröder-fotografie)

Backed by the impressive data from the EMPEROR-Preserved trial, Boehringer Ingelheim GmbH and Eli Lilly and Company are busy preparing supplementary filings for Jardiance which if successful – as seems highly likely – will become the only therapy to improve outcomes in all heart failure patients, regardless of ejection fraction or diabetes status.

Jardiance (empagliflozin) took center stage at the recent virtual European Society of Cardiology meeting, with results from the 5,988-patient study...

More from Cardiovascular

Aerovate Tanks On Trial Catastrophe
Mar 10 2025
• By Elizabeth Cairns
A disastrous Phase II miss for the pulmonary arterial hypertension candidate AV-101 leaves Aerovate drifting. Could Gossamer stand to benefit?
Cagrisema Leads The Charge For 2025
Mar 10 2025
• By Elizabeth Cairns
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
Evidence Growing For GLP-1s To Treat Alzheimer’s And Parkinson’s
Mar 10 2025
• By Andrew McConaghie
GLP-1 receptor agonists could play a big role in tackling neurodegeneration and a new academic study has raised expectations of Novo Nordisk’s latest semaglutide Phase III results
Kerendia Could Be Next Jewel In Bayer's Pharma Crown
Mar 10 2025
• By Kevin Grogan
CEO Bill Anderson would not be drawn on whether the drug, currently approved for chronic kidney disease associated with type 2 diabetes, will hit a previous forecast of €3bn peak sales, but expansion into heart failure may make that figure look conservative.

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.